Characterization of polyethylene glycol-polyethyleneimine as a vector for alpha-synuclein siRNA delivery to PC12 cells for Parkinson's disease

CNS Neuroscience and Therapeutics

Volumn 20, Issue 1, 2014, Pages 76-85

  Liu, Yun Yun ^a   Yang, Xing Yi ^b   Li, Zhong ^a   Liu, Zhong Lin ^c   Cheng, Du ^b   Wang, Yong ^b   Wen, Xiao Jun ^c   Hu, Jing Yang ^c   Liu, Jun ^c   Wang, Li Min ^d   Wang, Hui Jun ^b  

^a THE SIXTH AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

^c SOUTHERN MEDICAL UNIVERSITY   (China)

^d GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

Alpha synuclein; Gene therapy; Nanomedicine; Parkinson's disease; Polyethylene glycol polyethyleneimine; RNA interference

Indexed keywords

ALPHA SYNUCLEIN; MACROGOL; MESSENGER RNA; POLYETHYLENEIMINE; SMALL INTERFERING RNA;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL VIABILITY; CELLULAR DISTRIBUTION; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; CYTOTOXICITY; CYTOTOXICITY ASSAY; ENDOSOME; FLOW CYTOMETRY; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENETIC TRANSFECTION; IN VITRO GENE TRANSFER; NONHUMAN; PARKINSON DISEASE; PARTICLE SIZE; PC12 CELL; RAT; RNA VECTOR; ZETA POTENTIAL;

ALPHA-SYNUCLEIN; GENE THERAPY; NANOMEDICINE; PARKINSON'S DISEASE; POLYETHYLENE GLYCOL-POLYETHYLENEIMINE; RNA INTERFERENCE;

ALPHA-SYNUCLEIN; ANIMALS; APOPTOSIS; CELL NUCLEUS SHAPE; CELL SURVIVAL; DOWN-REGULATION; ENDOSOMES; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; INTRACELLULAR SPACE; NEUROTOXINS; PARKINSON DISEASE; PARTICLE SIZE; PC12 CELLS; POLYETHYLENE GLYCOLS; POLYETHYLENEIMINE; RATS; RNA, MESSENGER; RNA, SMALL INTERFERING; TETRAZOLIUM SALTS; THIAZOLES;

EID: 84890531744     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/cns.12176     Document Type: Article

References (46)

1. Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991;114(Pt 5):2283-2301.
2. Savitt JM, Dawson VL, Dawson TM. Diagnosis and treatment of Parkinson disease: molecules to medicine. J Clin Invest 2006;116:1744-1754.
3. Shaltiel-Karyo R, Davidi D, Frenkel-Pinter M, Ovadia M, Segal D, Gazit E. Differential inhibition of alpha-synuclein oligomeric and fibrillar assembly in parkinson's disease model by cinnamon extract. Biochim Biophys Acta 2012;1820:1628-1635.
4. Bellucci A, Navarria L, Zaltieri M, Missale C, Spano P. Alpha-synuclein synaptic pathology and its implications in the development of novel therapeutic approaches to cure Parkinson's disease. Brain Res 2012;1432:95-113.
5. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature 1997;388:839-840.
6. Rohn TT. Targeting alpha-synuclein for the treatment of Parkinson's disease. CNS Neurol Disord Drug Targets 2012;11:174-179.
7. Lewis J, Melrose H, Bumcrot D, et al. In vivo silencing of alpha-synuclein using naked siRNA. Mol Neurodegener 2008;3:19.
8. Wettergren EE, Gussing F, Quintino L, Lundberg C. Novel disease-specific promoters for use in gene therapy for Parkinson's disease. Neurosci Lett 2012;530:29-34.
9. Berry AL, Foltynie T. Gene therapy: a viable therapeutic strategy for Parkinson's disease? J Neurol 2011;258:179-188.
10. Karagiannis TC, El-Osta A. RNA interference and potential therapeutic applications of short interfering RNAs. Cancer Gene Ther 2005;12:787-795.
11. Pack DW, Hoffman AS, Pun S, Stayton PS. Design and development of polymers for gene delivery. Nat Rev Drug Discov 2005;4:581-593.
12. Huang PI, Lo WL, Cherng JY, Chien Y, Chiou GY, Chiou SH. Non-viral delivery of RNA interference targeting cancer cells in cancer gene therapy. Curr Gene Ther 2012;12:275-284.
13. Rogers ML, Rush RA. Non-viral gene therapy for neurological diseases, with an emphasis on targeted gene delivery. J Control Release 2012;157:183-189.
14. David S, Pitard B, Benoit JP, Passirani C. Non-viral nanosystems for systemic siRNA delivery. Pharmacol Res 2010;62:100-114.
15. Shen H, Sun T, Ferrari M. Nanovector delivery of siRNA for cancer therapy. Cancer Gene Ther 2012;19:367-373.
16. Kesharwani P, Gajbhiye V, Jain NK. A review of nanocarriers for the delivery of small interfering RNA. Biomaterials 2012;33:7138-7150.
17. Liu Y, Liu Z, Wang Y, et al. Investigation of the performance of PEG-PEI/ROCK-II-siRNA complexes for Alzheimer's disease in vitro. Brain Res 2013;1490:43-51.
18. Braithwaite SP, Stock JB, Mouradian MM. Alpha-synuclein phosphorylation as a therapeutic target in Parkinson's disease. Rev Neurosci 2012;23:191-198.
19. Wang MS, Boddapati S, Emadi S, Sierks MR. Curcumin reduces alpha-synuclein induced cytotoxicity in Parkinson's disease cell model. BMC Neurosci 2010;11:57.
20. Myohanen TT, Hannula MJ, Van Elzen R, et al. A prolyl oligopeptidase inhibitor, KYP-2047, reduces alpha-synuclein protein levels and aggregates in cellular and animal models of Parkinson's disease. Br J Pharmacol 2012;166:1097-1113.
21. Shaltiel-Karyo R, Frenkel-Pinter M, Egoz-Matia N, et al. Inhibiting alpha-synuclein oligomerization by stable cell-penetrating beta-synuclein fragments recovers phenotype of Parkinson's disease model flies. PLoS ONE 2010;5:e13863.
22. Khodr CE, Sapru MK, Pedapati J, et al. An alpha-synuclein AAV gene silencing vector ameliorates a behavioral deficit in a rat model of Parkinson's disease, but displays toxicity in dopamine neurons. Brain Res 2011;1395:94-107.
23. McCormack AL, Mak SK, Henderson JM, Bumcrot D, Farrer MJ, Di Monte DA. Alpha-synuclein suppression by targeted small interfering RNA in the primate substantia nigra. PLoS ONE 2010;5:e12122.
24. Chen Y, Lian G, Liao C, et al. Characterization of polyethylene glycol-grafted polyethylenimine and superparamagnetic iron oxide nanoparticles (PEG-g-PEI-SPION) as an MRI-visible vector for siRNA delivery in gastric cancer in vitro and in vivo. J Gastroenterol 2013;48:809-821.
25. Liang Y, Liu Z, Shuai X, et al. Delivery of cationic polymer-siRNA nanoparticles for gene therapies in neural regeneration. Biochem Biophys Res Commun 2012;421:690-695.
26. Wei J, Cheang T, Tang B, et al. The inhibition of human bladder cancer growth by calcium carbonate/CaIP6 nanocomposite particles delivering AIB1 siRNA. Biomaterials 2013;34:1246-1254.
27. Wang W, Cheng D, Gong F, Miao X, Shuai X. Design of multifunctional micelle for tumor-targeted intracellular drug release and fluorescent imaging. Adv Mater 2012;24:115-120.
28. Xu Z, Cawthon D, McCastlain KA, et al. Selective alterations of transcription factors in MPP+-induced neurotoxicity in PC12 cells. Neurotoxicology 2005;26:729-737.
29. Shafer TJ, Atchison WD. Transmitter, ion channel and receptor properties of pheochromocytoma (PC12) cells: a model for neurotoxicological studies. Neurotoxicology 1991;12:473-492.
30. 2+ signaling and caspase-3 activity in neuronal PC12 cells. Cell Mol Neurobiol 2013;33:205-212.
31. Greene LA, Rein G. Synthesis, storage and release of acetylcholine by a noradrenergic pheochromocytoma cell line. Nature 1977;268:349-351.
32. Greene LA, Rein G. Release, storage and uptake of catecholamines by a clonal cell line of nerve growth factor (NGF) responsive pheo-chromocytoma cells. Brain Res 1977;129:247-263.
33. Cai X, Jia H, Liu Z, et al. Polyhydroxylated fullerene derivative C(60)(OH)(24) prevents mitochondrial dysfunction and oxidative damage in an MPP(+) -induced cellular model of Parkinson's disease. J Neurosci Res 2008;86:3622-3634.
34. Xu J, Wei C, Xu C, et al. Rifampicin protects PC12 cells against MPP+-induced apoptosis and inhibits the expression of an alpha-synuclein multimer. Brain Res 2007;1139:220-225.
35. Li DW, Li GR, Lu Y, et al. Alpha-lipoic acid protects dopaminergic neurons against MPP+-induced apoptosis by attenuating reactive oxygen species formation. Int J Mol Med 2013;32:108-114.
36. Gao HL, Li C, Nabeka H, et al. Attenuation of MPTP/MPP(+) toxicity in vivo and in vitro by an 18-mer peptide derived from prosaposin. Neuroscience 2013;236:373-393.
37. Pizarro JG, Junyent F, Verdaguer E, et al. Effects of MPP+ on the molecular pathways involved in cell cycle control in B65 neuroblastoma cells. Pharmacol Res 2010;61:391-399.
38. Hartley A, Stone JM, Heron C, Cooper JM, Schapira AH. Complex I inhibitors induce dose-dependent apoptosis in PC12 cells: relevance to Parkinson's disease. J Neurochem 1994;63:1987-1990.
39. Itano Y, Kitamura Y, Nomura Y. 1-Methyl-4-phenylpyridinium (MPP+)-induced cell death in PC12 cells: inhibitory effects of several drugs. Neurochem Int 1994;25:419-424.
40. Chen T, Zhu J, Zhang C, Huo K, Fei Z, Jiang XF. Protective effects of SKF-96365, a non-specific inhibitor of SOCE, against MPP+-induced cytotoxicity in PC12 cells: potential role of Homer1. PLoS ONE 2013;8:e55601.
41. Han YS, Lee CS. Antidepressants reveal differential effect against 1-methyl-4-phenylpyridinium toxicity in differentiated PC12 cells. Eur J Pharmacol 2009;604:36-44.
42. Zhu M, Li W, Lu C. Role of alpha-synuclein protein levels in mitochondrial morphology and cell survival in cell lines. PLoS ONE 2012;7:e36377.
43. Jethva PN, Kardani JR, Roy I. Modulation of alpha-synuclein aggregation by dopamine in the presence of MPTP and its metabolite. FEBS J 2011;278:1688-1698.
44. Dauer W, Kholodilov N, Vila M, et al. Resistance of alpha -synuclein null mice to the parkinsonian neurotoxin MPTP. Proc Natl Acad Sci USA 2002;99:14524-14529.
45. Vila M, Vukosavic S, Jackson-Lewis V, Neystat M, Jakowec M, Przedborski S. Alpha-synuclein up-regulation in substantia nigra dopaminergic neurons following administration of the parkinsonian toxin MPTP. J Neurochem 2000;74:721-729.
46. Wu F, Poon WS, Lu G, et al. Alpha-synuclein knockdown attenuates MPP+ induced mitochondrial dysfunction of SH-SY5Y cells. Brain Res 2009;1292:173-179.